Project Title

Investigating the effects of chronic Factor X anticoagulant exposure and dementia risk.

Project Summary

Long-term oral anticoagulant (OAC) therapy is widely used to prevent clots in individuals with medical conditions such as atrial fibrillation (AF) and venous thromboembolism (VTE). However, the impact of chronic OAC exposure on the risk of cognitive decline and dementia is unclear. It is known that vascular risk factors play an important role in the development and progression of Alzheimer's disease (AD) and alterations to vascular walls are widely reported in patients with AD and other dementias.

Blood platelets are the key regulators of haemostasis and are vital in maintaining vascular integrity. Growing evidence indicates that blood platelets may play a role in the progression of cognitive decline and AD, and may have a role in promoting AD pathology. They are the richest source of Amyloid Precursor Protein (APP) in the body and mediate the two major APP cleavage pathways.

One of these enzymes, A Disintegrin And Metalloproteinase (ADAM) 10, is decreased in platelets of AD patients suggesting that aberrant APP processing by platelets may have a contributory role in AD development or progression. Recent studies showed that the coagulation factor Xa (FXa) has a physiological role in activating ADAM10 in platelets. This novel finding may have implications for patients on long-term OAC therapy, particularly those utilising FXa inhibitors as FXa is capable of mediating several other coagulation-independent biological processes.

This project aims to examine FXa inhibition on the risk of cognitive decline and investigates the molecular mechanisms underlying this association.

Blood Disorder

  • Atrial Fibrillation
  • Venous Thromboembolism

Patient Recruitment Details

Patient recruitment status: Not commenced

Number of Patients

To be confirmed.

Partner Organisations